Eversept Partners’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25.3M | Sell |
481,833
-1,303,342
| -73% | -$68.9M | 1.31% | 18 |
|
|
2026
Q1 | $98.5M | Sell |
1,785,175
-894,546
| -33% | -$48.5M | 5.2% | 4 |
|
|
2025
Q4 | $131M | Buy |
2,679,721
+559,275
| +26% | +$26.1M | 6.62% | 3 |
|
|
2025
Q3 | $91.5M | Sell |
2,120,446
-121,942
| -5% | -$4.76M | 6.31% | 3 |
|
|
2025
Q2 | $86.1M | Sell |
2,242,388
-380,858
| -15% | -$14.6M | 7.92% | 3 |
|
|
2025
Q1 | $102M | Sell |
2,623,246
-1,038,522
| -28% | -$38M | 10.32% | 2 |
|
|
2024
Q4 | $124M | Sell |
3,661,768
-395,438
| -10% | -$14.2M | 10.99% | 3 |
|
|
2024
Q3 | $166M | Buy |
4,057,206
+589,126
| +17% | +$24.1M | 11.36% | 1 |
|
|
2024
Q2 | $134M | Sell |
3,468,080
-303,914
| -8% | -$12.8M | 9.14% | 2 |
|
|
2024
Q1 | $162M | Buy |
3,771,994
+799,040
| +27% | +$33M | 10.79% | 2 |
|
|
2023
Q4 | $110M | Sell |
2,972,954
-286,388
| -9% | -$10.3M | 9.68% | 2 |
|
|
2023
Q3 | $118M | Buy |
3,259,342
+378,330
| +13% | +$13.4M | 10% | 2 |
|
|
2023
Q2 | $104M | Sell |
2,881,012
-850,487
| -23% | -$30.5M | 8.68% | 3 |
|
|
2023
Q1 | $134M | Buy |
3,731,499
+241,042
| +7% | +$8.43M | 9.34% | 4 |
|
|
2022
Q4 | $124M | Buy |
3,490,457
+551,387
| +19% | +$18.4M | 10.84% | 1 |
|
|
2022
Q3 | $87.3M | Buy |
2,939,070
+1,663,773
| +130% | +$63.1M | 7.56% | 3 |
|
|
2022
Q2 | $69.9M | Buy |
1,275,297
+267,967
| +27% | +$14.8M | 4.97% | 6 |
|
|
2022
Q1 | $55.5M | Buy |
1,007,330
+553,566
| +122% | +$30.1M | 4.26% | 6 |
|
|
2021
Q4 | $25M | Buy |
453,764
+132,441
| +41% | +$6.89M | 1.6% | 19 |
|
|
2021
Q3 | $15.4M | Buy |
321,323
+231,180
| +256% | +$11.6M | 1.07% | 28 |
|
|
2021
Q2 | $4.61M | Sell |
90,143
-591,622
| -87% | -$28.4M | 0.31% | 50 |
|
|
2021
Q1 | $31.1M | Sell |
681,765
-75,500
| -10% | -$3.43M | 2.33% | 16 |
|
|
2020
Q4 | $35.2M | Buy |
757,265
+705,767
| +1,370% | +$32.4M | 4.13% | 8 |
|
|
2020
Q3 | $2.45M | Sell |
51,498
-130,312
| -72% | -$6.53M | 0.55% | 33 |
|
|
2020
Q2 | $9.27M | Sell |
181,810
-226,647
| -55% | -$11.6M | 1.27% | 20 |
|
|
2020
Q1 | $19.9M | Sell |
408,457
-410,011
| -50% | -$21.9M | 4.94% | 7 |
|
|
2019
Q4 | $48.6M | Buy |
818,468
+32,000
| +4% | +$1.78M | 8.58% | 2 |
|
|
2019
Q3 | $42.3M | Buy |
786,468
+231,520
| +42% | +$11.9M | 13.13% | 1 |
|
|
2019
Q2 | $28.1M | Sell |
554,948
-87,600
| -14% | -$4.4M | 7.87% | 3 |
|
|
2019
Q1 | $34.1M | Buy |
642,548
+218,961
| +52% | +$10.9M | 9.94% | 2 |
|
|
2018
Q4 | $20.4M | Buy |
423,587
+192,160
| +83% | +$9.46M | 11.04% | 2 |
|
|
2018
Q3 | $11.7M | Buy |
231,427
+29,360
| +15% | +$1.49M | 5.15% | 6 |
|
|
2018
Q2 | $10.3M | Buy |
202,067
+20,800
| +11% | +$1.05M | 4.72% | 5 |
|
|
2018
Q1 | $8.95M | Buy |
+181,267
| New | +$8.44M | 4.16% | 9 |
|
Other funds holding GSK
JEST
Eversept Partners's GSK Position: Q2 2026 in Review
Eversept Partners reduced its GSK (GSK) stake by 73% in Q2 2026, selling an estimated $68.9M and leaving 481,833 shares worth $25.3M. The position accounts for 1.31% of the portfolio, ranked #18.
Eversept Partners first reported a position in GSK in Q1 2018 and has held it in 34 quarters since. The position peaked at $166M in Q3 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Eversept Partners held 481,833 shares of GSK worth $25.3M as of Q2 2026.
- Eversept Partners sold 1,303,342 GSK shares in Q2 2026, an estimated $68.9M.
- GSK made up 1.31% of Eversept Partners's portfolio in Q2 2026, its #18 holding.
- Eversept Partners first reported a position in GSK in Q1 2018 and has held it in 34 quarters since.
- Eversept Partners's GSK position peaked at $166M in Q3 2024.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.